Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Research & Development for 14 consecutive years, with $187.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 12.65% year-over-year to $187.0 million; the TTM figure through Mar 2026 stood at $771.2 million (up 12.5% YoY), while the FY2025 annual figure was $750.0 million, up 7.45% from the prior year.
• Research & Development fell to $187.0 million in Q1 2026 per RARE's latest filing, from $203.3 million in the prior quarter.
• Across five years, Research & Development topped out at $237.3 million in Q3 2022 and bottomed at $143.2 million in Q1 2022.
• Historically, Research & Development has averaged $175.8 million across 5 years, with a median of $166.0 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development soared 109.23% — and 2023, when it plunged 33.73%.
• Ultragenyx Pharmaceutical's Research & Development stood at $170.8 million in 2022, then dropped by 6.26% to $160.1 million in 2023, then increased by 17.36% to $187.9 million in 2024, then rose by 8.18% to $203.3 million in 2025, then fell by 8.01% to $187.0 million in 2026.
• Business Quant data shows RARE's Research & Development at $187.0 million in Q1 2026, $203.3 million in Q4 2025, and $216.2 million in Q3 2025.